IMPLANET: Revenue Up 18% in Q1, Driven by the US and SMTP
IMPLANET reports a revenue of EUR 3.03 million in the first quarter of 2026, an increase of 18% compared to the same period in 2025, confirming a growth momentum sustained over seven quarters. However, this overall progress relies on contrasting drivers: a spectacular expansion in the United States and more than doubling of ultrasonic scalpel sales, while the historic spinal implant business declines by 4% and export markets contract by 19%.
Uneven Performance Distribution in Q1
The first quarter figures reveal an uneven distribution of performance. The Spinal Implants business, the historical core of the group, recorded EUR 2.02 million, down from EUR 2.11 million in Q1 2025, a decline of 4%. This is attributed to the replacement of the OSD range with the new JSS hybrid posterior fixation system, suggesting a portfolio transition rather than a structural weakness. Conversely, the medical equipment distribution with the SMTP ultrasonic scalpel saw an increase by 2.12 times: EUR 0.99 million compared to EUR 0.47 million a year earlier, an increase of 112%. Geographically, the contrast is even more marked. France progressed moderately by 8% to EUR 1.26 million. The United States surged: EUR 0.89 million in Q1 2026 compared to EUR 0.335 million in Q1 2025, a 167% increase. This advance is directly linked to the deployment of SMTP. However, the rest of the world fell by 19% to EUR 0.88 million, which management explains by a cautious financial risk management, including postponing orders in the Middle East and Asia for the coming quarters.
Financial Position as of March 31, 2026
As of March 31, 2026, IMPLANET has a cash reserve of EUR 1.39 million. The management states that, considering the anticipated commercial developments and payment facilities with Sanyou Medical, the company estimates it will be able to cover its financing needs for the next twelve months. This positioning reveals a tight cash flow situation: with quarterly revenue of EUR 3 million and cash reserves of EUR 1.39 million, the margin for maneuver remains narrow, even though the strategic partnership with Sanyou Medical and growth prospects seem to provide support.
IMPLANET's Clear Ambitions for 2026
IMPLANET has clear ambitions for 2026. The group intends to strengthen its presence in the United States by recruiting an experienced sales force and accelerating the deployment of JAZZ® and products co-developed with Sanyou Medical. Strategically, the company plans to position itself as the exclusive distributor in Europe and the United States for Sanyou Medical's assistive technologies. It also plans to launch the SMTP Quntas range, consisting of ultrasonic scalpels with suction, marking an entry into the markets of surgical revision and tumor surgery. Finally, IMPLANET aims to extend the distribution of JAZZ® in China, described as the world's largest spinal market by volume. These initiatives must be finalized in a demanding regulatory context: the company must complete the registration of existing products under the European Medical Device Regulation and the FDA's 510(k). The main challenge for investors lies in IMPLANET's ability to transform its American growth and distribution dynamics into sustainable profitability, while stabilizing its historic spinal implants business.
